- Home
- MOLN vs INBX Comparison
MOLN vs INBX Comparison
Compare MOLN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- INBX
- Stock Information
- Founded
- MOLN 2004
- INBX 2010
- Country
- MOLN Switzerland
- INBX United States
- Employees
- MOLN N/A
- INBX N/A
- Industry
- MOLN
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- INBX Health Care
- Exchange
- MOLN Nasdaq
- INBX Nasdaq
- Market Cap
- MOLN 214.4M
- INBX 218.9M
- IPO Year
- MOLN 2021
- INBX 2020
- Fundamental
- Price
- MOLN $5.31
- INBX $14.86
- Analyst Decision
- MOLN
- INBX Hold
- Analyst Count
- MOLN 0
- INBX 1
- Target Price
- MOLN N/A
- INBX N/A
- AVG Volume (30 Days)
- MOLN 26.6K
- INBX 71.2K
- Earning Date
- MOLN 08-26-2024
- INBX 11-14-2024
- Dividend Yield
- MOLN N/A
- INBX N/A
- EPS Growth
- MOLN N/A
- INBX N/A
- EPS
- MOLN N/A
- INBX 119.38
- Revenue
- MOLN $7,105,397.00
- INBX $1,568,000.00
- Revenue This Year
- MOLN N/A
- INBX N/A
- Revenue Next Year
- MOLN $29.41
- INBX N/A
- P/E Ratio
- MOLN N/A
- INBX $0.12
- Revenue Growth
- MOLN N/A
- INBX 19.24
- 52 Week Low
- MOLN $3.32
- INBX $10.80
- 52 Week High
- MOLN $12.70
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- MOLN 43.84
- INBX 52.04
- Support Level
- MOLN $5.26
- INBX $14.19
- Resistance Level
- MOLN $5.65
- INBX $15.22
- Average True Range (ATR)
- MOLN 0.20
- INBX 0.66
- MACD
- MOLN -0.04
- INBX 0.00
- Stochastic Oscillator
- MOLN 6.85
- INBX 49.13
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.